Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
220
datasets available to search
ShareScore release 0.9.0
Dataset results
220 results for “Alzheimer dementia”
Atrophy Pattern Maps of Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, and Frontotemporal Dementia
<p>The files contain voxel-wise t-statistics maps contrasting deformation based morphometry (DBM) measurements of Alzheimer's disease (AD), Parkinson's disease (PD), mild cognitive impairment (MCI), and fronto-temporal dementia (FTD) patients against matched normal controls.</p> <p>AD and MCI maps are based on ADNI data, available at:</p> <p>PD map is based on PPMI data, available at:</p> <p>FTD map is based on NIFD data, available at:</p> <p>For more information regarding the participants and method details, see:</p> <p>Dadar, Mahsa, et al. "White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia." <em>Neurobiology of aging</em> 111 (2022): 54-63.</p>
Extraction of clinical phenotypes for Alzheimer disease dementia from clinical notes using natural language processing
<p><strong>Objectives</strong></p> <p>There is much interest in utilizing clinical data for developing prediction models for Alzheimer disease (AD) risk, progression, and outcomes. Existing studies have mostly utilized curated research registries, image analysis, and structured Electronic Health Record (EHR) data. However, much critical information resides in relatively inaccessible unstructured clinical notes within the EHR.</p> <p><strong>Materials and Methods</strong></p> <p>We developed a natural language processing (NLP)-based pipeline to extract AD-related clinical phenotypes, documenting strategies for success and assessing the utility of mining unstructured clinical notes. We evaluated the pipeline against gold-standard manual annotations performed by two clinical dementia experts for AD-related clinical phenotypes including medical comorbidities, biomarkers, neurobehavioral test scores, behavioral indicators of cognitive decline, family history, and neuroimaging findings.</p> <p><strong>Results</strong></p> <p>Documentation rates for each phenotype varied in the structured versus unstructured EHR. Inter-annotator agreement was high (Cohen's kappa = 0.72–1) and positively correlated with the NLP-based phenotype extraction pipeline's performance (average F1-score = 0.65-0.99) for each phenotype.</p> <p><strong>Discussion</strong></p> <p>We developed an automated NLP-based pipeline to extract informative phenotypes that may improve the performance of eventual machine-learning predictive models for AD. In the process, we examined documentation practices for each phenotype relevant to the care of AD patients and identified factors for success.</p> <p><strong>Conclusion</strong></p> <p>Success of our NLP-based phenotype extraction pipeline depended on domain-specific knowledge and focus on a specific clinical domain instead of maximizing generalizability. </p>
Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
ClinicalTrials.gov study NCT04948866. IPD Sharing: YES. Countries: 1. Publications: 1.
Extraction of clinical phenotypes for Alzheimer disease dementia from clinical notes using natural language processing
Open the record for dataset details and reuse information.
Healthy lifestyle and the risk of Alzheimer's dementia: Findings from two longitudinal studies
<p><strong>Objective</strong><br> To quantify the impact of a healthy lifestyle on the risk of Alzheimer's dementia.</p> <p><strong>Methods</strong><br> Using data from the Chicago Health and Aging Project (CHAP n=1,845) and the Rush Memory and Aging Project (MAP n=920), we defined a healthy lifestyle score on the basis of non-smoking, >=150 min/week moderate/vigorous intensity physical activity, light-to-moderate alcohol consumption, high-quality MIND diet (upper 40%), and engagement in late-life cognitive activities (upper 40%), giving an overall score ranging from 0 to 5. Cox proportional hazard models were used for each cohort to estimate the hazard ratio (HR) and 95% confidence interval (95%CI) of the lifestyle score with Alzheimer's dementia and a random effect meta-analysis was used to pool the results.</p> <p><strong>Results</strong><br> During a median follow-up of 5.8 years in CHAP and 6.0 years in MAP, 379 and 229 participants, respectively had incident Alzheimer's dementia. In multivariable-adjusted models, the pooled HR (95%CI) of Alzheimer's dementia across two cohorts was 0.73 (95%CI, 0.66-0.80) per each additional healthy lifestyle factor. Compared to participants with 0-1 healthy lifestyle factor, the risk of Alzheimer's dementia was 37% lower (pooled HR 0.63; 95%CI, 0.47-0.84) in those with 2-3 healthy lifestyle factors, and 60% lower (pooled HR 0.40; 95%CI, 0.28-0.56) in those with 4-5 healthy lifestyle factors. </p> <p><strong>Conclusion</strong><br> A healthy lifestyle as a composite score is associated with a substantially lower risk of Alzheimer's dementia.</p>
GUT MICROBIOME COMPOSITION IN ALZHEIMER'S DEMENTIA PATIENTS: REPORT FROM PILOT STUDY IN KAZAKHSTAN
<p>Sequencing raw data of microbiome in fastq format</p>
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
ClinicalTrials.gov study NCT03594123. IPD Sharing: YES. Countries: 1. Publications: 3.
Partners in Dementia Care: A Telephone Care Consultation Intervention Provided to Veterans in Partnership With Local Alzheimer's Association Chapters
ClinicalTrials.gov study NCT00291161. IPD Sharing: UNDECIDED. Countries: 1. Publications: 13.
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
ClinicalTrials.gov study NCT03548584. IPD Sharing: YES. Countries: 1. Publications: 7.
Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias
ClinicalTrials.gov study NCT03244917. IPD Sharing: NO. Countries: 1. Publications: 3.
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
ClinicalTrials.gov study NCT02569398. IPD Sharing: Not stated. Countries: 13. Publications: 1.
Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
ClinicalTrials.gov study NCT03724942. IPD Sharing: YES. Countries: 1. Publications: 1.
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's
ClinicalTrials.gov study NCT04623242. IPD Sharing: YES. Countries: 8. Publications: 13.
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
ClinicalTrials.gov study NCT02783573. IPD Sharing: YES. Countries: 18. Publications: 2.
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Ope
ClinicalTrials.gov study NCT00948766. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
ClinicalTrials.gov study NCT03422250. IPD Sharing: NO. Countries: 1. Publications: 2.
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's
ClinicalTrials.gov study NCT06424236. IPD Sharing: YES. Countries: 6. Publications: 13.
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
ClinicalTrials.gov study NCT03620981. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
ClinicalTrials.gov study NCT01922258. IPD Sharing: YES. Countries: 9. Publications: 5.
Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
ClinicalTrials.gov study NCT00495820. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.